AU2014241891B2 - Ribotoxin molecules derived from sarcin and other related fungal ribotoxins - Google Patents

Ribotoxin molecules derived from sarcin and other related fungal ribotoxins Download PDF

Info

Publication number
AU2014241891B2
AU2014241891B2 AU2014241891A AU2014241891A AU2014241891B2 AU 2014241891 B2 AU2014241891 B2 AU 2014241891B2 AU 2014241891 A AU2014241891 A AU 2014241891A AU 2014241891 A AU2014241891 A AU 2014241891A AU 2014241891 B2 AU2014241891 B2 AU 2014241891B2
Authority
AU
Australia
Prior art keywords
sarcin
modified
molecule
ribotoxin
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014241891A
Other languages
English (en)
Other versions
AU2014241891A1 (en
Inventor
Francis Joseph Carr
Kurt R. Gehlsen
Arron HEARN
Timothy David Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Corp Technologies Inc
Original Assignee
Research Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp Technologies Inc filed Critical Research Corp Technologies Inc
Publication of AU2014241891A1 publication Critical patent/AU2014241891A1/en
Application granted granted Critical
Publication of AU2014241891B2 publication Critical patent/AU2014241891B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/38—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Aspergillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
    • C12Y301/2701—Endoribonucleases producing 3'-phosphomonoesters (3.1.27) rRNA endonuclease (3.1.27.10)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2014241891A 2013-03-14 2014-03-03 Ribotoxin molecules derived from sarcin and other related fungal ribotoxins Ceased AU2014241891B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361783589P 2013-03-14 2013-03-14
US61/783,589 2013-03-14
US201361902972P 2013-11-12 2013-11-12
US61/902,972 2013-11-12
PCT/US2014/020035 WO2014158770A1 (en) 2013-03-14 2014-03-03 Ribotoxin molecules derived from sarcin and other related fungal ribotoxins

Publications (2)

Publication Number Publication Date
AU2014241891A1 AU2014241891A1 (en) 2015-09-17
AU2014241891B2 true AU2014241891B2 (en) 2017-09-14

Family

ID=51625052

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014241891A Ceased AU2014241891B2 (en) 2013-03-14 2014-03-03 Ribotoxin molecules derived from sarcin and other related fungal ribotoxins

Country Status (11)

Country Link
US (2) US9603911B2 (cg-RX-API-DMAC10.html)
EP (1) EP2971038B1 (cg-RX-API-DMAC10.html)
JP (1) JP6203372B2 (cg-RX-API-DMAC10.html)
AU (1) AU2014241891B2 (cg-RX-API-DMAC10.html)
CA (1) CA2903252C (cg-RX-API-DMAC10.html)
DK (1) DK2971038T3 (cg-RX-API-DMAC10.html)
ES (1) ES2765302T3 (cg-RX-API-DMAC10.html)
PL (1) PL2971038T3 (cg-RX-API-DMAC10.html)
PT (1) PT2971038T (cg-RX-API-DMAC10.html)
SI (1) SI2971038T1 (cg-RX-API-DMAC10.html)
WO (1) WO2014158770A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903252C (en) * 2013-03-14 2023-01-17 Research Corporation Technologies, Inc. Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
WO2017053290A1 (en) * 2015-09-23 2017-03-30 Research Corporation Technologies, Inc. Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
EA202191610A1 (ru) * 2018-12-07 2021-10-25 Джиноум Протекшн, Инк. Композиции, полученные из сконструированного флагеллина, и их применение
WO2022038152A1 (en) * 2020-08-17 2022-02-24 Atb Therapeutics Recombinant immunotoxin comprising a ribotoxin or rnase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU654563B2 (en) * 1991-07-24 1994-11-10 Imperial Chemical Industries Plc Proteins
US8114969B2 (en) 2003-10-01 2012-02-14 Isis Innovation, Ltd. Immunotoxin derived from a recombinant human autoantibody and method of using thereof
EP1846432A4 (en) 2005-01-12 2008-11-19 Proteonova Inc METHOD FOR PRODUCING TARGETED THERAPEUTIC AGENTS
CA2903252C (en) * 2013-03-14 2023-01-17 Research Corporation Technologies, Inc. Ribotoxin molecules derived from sarcin and other related fungal ribotoxins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
spencer c alford et al, "alpha-Sarcin catalytic activity is not required for cytotoxicity", BMC BIOCHEMISTRY, vol. 10, doi:10.1186/1471-2091-10-9, (20090403), URL: http://bmcbiochem.biomedcentral.com/articles/10.1186/1471-2091-10-9, *

Also Published As

Publication number Publication date
EP2971038A4 (en) 2016-11-23
PT2971038T (pt) 2020-01-20
EP2971038B1 (en) 2019-12-04
JP6203372B2 (ja) 2017-09-27
PL2971038T3 (pl) 2020-04-30
US9976131B2 (en) 2018-05-22
CA2903252A1 (en) 2014-10-02
CA2903252C (en) 2023-01-17
WO2014158770A1 (en) 2014-10-02
JP2016512251A (ja) 2016-04-25
US20170204387A1 (en) 2017-07-20
EP2971038A1 (en) 2016-01-20
SI2971038T1 (sl) 2020-02-28
ES2765302T3 (es) 2020-06-08
AU2014241891A1 (en) 2015-09-17
US9603911B2 (en) 2017-03-28
DK2971038T3 (da) 2020-01-27
US20160106819A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
JP7442879B2 (ja) Ｍｈｃクラスｉエピトープ送達ポリペプチド
US11976101B2 (en) Multi-level specific targeting of cancer cells
US20160031985A1 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
WO2017157334A1 (zh) 抗pd-l1纳米抗体及其编码序列和用途
WO2015184941A1 (zh) 一种cd7纳米抗体、其编码序列及应用
JP2015531350A (ja) 末端修飾を有する抗原結合分子
EA028178B1 (ru) Улучшенные связывающие сывороточный альбумин варианты
US9976131B2 (en) Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
US20230250189A1 (en) Humanized Antibodies Against PSMA
TW202340240A (zh) 多特異性抗體及其藥物用途
US20250059295A1 (en) Steap2 directed t-cell engagers and compositions thereof
Marshall et al. Engineering and characterization of a novel fusion protein incorporating B7. 2 and an anti–ErbB-2 single-chain antibody fragment for the activation of Jurkat T cells
EP2533811A2 (en) Multimeric proteins comprising immunoglobulin constant domains
CN108300725A (zh) 可溶性单链抗体超抗原融合基因及蛋白和其制备与应用
WO2020108636A1 (zh) 全人抗gitr抗体及其制备方法
JP2025532652A (ja) Ｃｄ１３７およびｃｄ２２８に特異的な新規融合タンパク質
WO2017053290A1 (en) Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
US20150030593A1 (en) Compositions of penetration-enhanced targeting proteins and methods of use
KR20200082345A (ko) 암배항원을 표적화하는 재조합 면역독소 및 이를 포함하는 암 예방 또는 치료용 약학 조성물

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired